Drugs Made In America Acquisition II Corp. has announced a significant financing move, securing $1.4 million in convertible notes as part of its ongoing efforts to solidify its financial foundation. This financing is crucial as the company explores a potential business combination with Alpha AI Biotech Group.
The company’s recent SEC filing, dated November 18, 2026, highlights the consolidation of previous notes into a new convertible promissory note, which will mature on June 30, 2027. This strategic decision aims to streamline the company’s financial obligations while extending the maturity of previous notes that were set to expire this December.
Background
Drugs Made In America Acquisition II Corp. operates in the blank check sector, as indicated by its SIC code 6770. The company is listed on the Nasdaq under the tickers DMII, DMIIR, and DMIIU. It is categorized as a non-accelerated filer and an emerging growth company. This filing follows a series of recent filings, including a 10-Q on November 16, 2026, and a Schedule 13G on November 13, 2026.
What the Filing Says
The SEC filing reveals that the company and its investor, Tal Alpha Yezum Vekidum Asakim (2003) Ltd., have reached a definitive agreement for $1.4 million in convertible notes financing. The filing states, “Following this installment, $700,000 of the Convertible Notes Financing has been funded and $700,000 remains available under the Agreement.” This financing is critical as the company prepares for potential growth through mergers.
Impact
This development may impact various stakeholders, including shareholders of Drugs Made In America Acquisition II Corp. and Alpha AI Biotech Group. The proposed business combination, which has a pre-money equity valuation of $600 million, could significantly alter the landscape for both companies. The deal is contingent on satisfactory due diligence and necessary approvals.
What's Next
The filing indicates that the proposal is subject to due diligence, audited financial statements, and the execution of definitive agreements. The company has also implemented a limited 30-day standstill period, which restricts competing transactions but allows for the evaluation of alternatives. This standstill is set to expire around December 3, 2026, unless extended or terminated earlier.
In summary, Drugs Made In America Acquisition II Corp. is taking strategic steps to secure its financial future while exploring a potentially transformative merger with Alpha AI Biotech Group. As the blank check industry continues to evolve, the actions of this company may set a precedent for others in the sector.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





